Table 4.
Apramycin activity in comparison with gentamicin, amikacin, tobramycin and plazomicin against engineered E. coli strains expressing individual aminoglycoside resistance mechanisms
| Resistance mechanism | MIC (mg/L) |
||||
|---|---|---|---|---|---|
| APR | GEN | AMK | TOB | PLZ | |
| None | 4 | 0.5 | 1–2 | 0.5 | 0.5 |
| AAC(6′)-I | 4 | 2 | 64 | 32–64 | 0.5 |
| AAC(6′)-II | 4 | 64 | 8 | 32–64 | 1 |
| AAC(3)-I | 8 | >64 | 1–2 | 1 | 0.5–1 |
| AAC(3)-II | 8 | >64 | 1 | 32 | 4 |
| AAC(3)-III | 4 | >64 | 0.5–1 | >64 | 0.5 |
| AAC(3)-IV | >64 | 2 | 1–2 | 2 | 0.5 |
| AAC(3)-VI | 4 | >64 | 1–2 | 4 | 1 |
| AAC(2′)-I | 2–4 | 4 | 1–2 | 8–16 | 8–16 |
| APH(3′)-I | 2 | 1–2 | 1–2 | 8 | 0.5 |
| APH(3′)-II | 4 | 0.5 | 8 | 0.5 | 0.5 |
| APH(3′)-III | 4 | 0.5 | 32 | 4–8 | 0.5 |
| APH(3′)-VI | 4 | 0.5 | 64 | 0.5 | 0.5–1 |
| APH(2′′)-II | 2–4 | >64 | 2–4 | 64 | 8 |
| APH(2′′)-IV | 4 | >64 | 1–2 | 32–64 | 8 |
| ANT(4′)-II | 2–4 | 0.5 | 1–2 | 0.5 | 0.5–1 |
| ANT(2′′)-I | 4 | 16–32 | 1 | 16–32 | 0.5 |
| armA | 2–4 | >64 | >64 | >64 | >64 |
| rmtB | 4 | >64 | >64 | >64 | >64 |
| rmtC | 2–4 | >64 | >64 | >64 | >64 |
| rmtF | 2–4 | >64 | >64 | >64 | >64 |
APR, apramycin; GEN, gentamicin; AMK, amikacin; TOB, tobramycin; PLZ, plazomicin.